These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31126975)

  • 1. Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.
    Chen D; Li Z; Cheng Q; Wang Y; Qian L; Gao J; Zhu JY
    J Clin Pathol; 2019 Sep; 72(9):588-596. PubMed ID: 31126975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
    Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
    World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing "stemness"-related markers.
    Kim H; Yoo JE; Cho JY; Oh BK; Yoon YS; Han HS; Lee HS; Jang JJ; Jeong SH; Kim JW; Park YN
    J Hepatol; 2013 Oct; 59(4):746-52. PubMed ID: 23685049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
    Chan AW; Tong JH; Chan SL; Lai PB; To KF
    Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models.
    Zhao Q; Zhou H; Liu Q; Cao Y; Wang G; Hu A; Ruan L; Wang S; Bo Q; Chen W; Hu C; Xu D; Tao F; Cao J; Ge Y; Yu Z; Li L; Wang H
    Oncotarget; 2016 Jul; 7(30):47431-47443. PubMed ID: 27329727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma.
    Su R; Nan H; Guo H; Ruan Z; Jiang L; Song Y; Nan K
    Hepatol Res; 2016 Dec; 46(13):1380-1391. PubMed ID: 26932478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM
    Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E
    Cells; 2020 May; 9(5):. PubMed ID: 32408542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma.
    Tanaka K; Tomita H; Hisamatsu K; Nakashima T; Hatano Y; Sasaki Y; Osada S; Tanaka T; Miyazaki T; Yoshida K; Hara A
    Oncotarget; 2015 Sep; 6(28):24722-32. PubMed ID: 26160842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
    Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
    Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perinodular ductular reaction/epithelial cell adhesion molecule loss in small hepatic nodules.
    Zhang Q; Zhang CS; Xin Q; Ma Z; Liu GQ; Liu BB; Wang FM; Gao YT; Du Z
    World J Gastroenterol; 2014 Aug; 20(31):10908-15. PubMed ID: 25152593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation.
    Zen C; Zen Y; Mitry RR; Corbeil D; Karbanov√° J; O'Grady J; Karani J; Kane P; Heaton N; Portmann BC; Quaglia A
    Liver Transpl; 2011 Aug; 17(8):943-54. PubMed ID: 21491582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.
    Wang H; Kohashi K; Yoshizumi T; Okumura Y; Tanaka Y; Shimokawa M; Iwasaki T; Aishima S; Maehara Y; Oda Y
    Hum Pathol; 2017 Jun; 64():69-75. PubMed ID: 28411180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer stem cells in hepatocellular carcinoma--an immunohistochemical study with histopathological association.
    Matthai SM; Ramakrishna B
    Indian J Med Res; 2015 Oct; 142(4):391-8. PubMed ID: 26609030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of hepatic stem cells compartment during hepatocarcinogenesis in a HBsAg HBV-transgenic mouse model.
    Anfuso B; El-Khobar KE; Ie SI; Avellini C; Radillo O; Raseni A; Tiribelli C; Sukowati CHC
    Sci Rep; 2018 Sep; 8(1):13168. PubMed ID: 30177788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired phosphate and tension homologue deleted on chromosome 10 expression and its prognostic role in radical surgery for hepatocellular carcinoma with family aggregation resulting from hepatitis B and liver cirrhosis.
    Zhong Y; Yan J; Deng M; Hu K; Yao Z; Zou Y; Xu R
    Exp Biol Med (Maywood); 2013 Aug; 238(8):866-73. PubMed ID: 23828588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
    Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
    World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation.
    Zeng Z; Ren J; O'Neil M; Zhao J; Bridges B; Cox J; Abdulkarim B; Schmitt TM; Kumer SC; Weinman SA
    BMC Cancer; 2012 Dec; 12():584. PubMed ID: 23216644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
    Zhou Y; Wang B; Wu J; Zhang C; Zhou Y; Yang X; Zhou J; Guo W; Fan J
    BMC Cancer; 2016 Jul; 16():506. PubMed ID: 27439521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
    Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
    BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics.
    Kim H; Park YN
    Dig Dis; 2014; 32(6):778-85. PubMed ID: 25376296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.